🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating around the world, with figures suggesting over 82 million new cases per year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, escalating drug resistance and the very limited therapeutic options presently on offer.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts hope that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, was also approved in concurrent days. This treatment, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This milestone signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

Based on findings released by a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The research involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have voiced positive views. The availability of a easy-to-administer therapy such as this is hailed as a "revolutionary step" for gonorrhoea control. This is deemed vital to alleviate the strain of the disease for individuals and to halt the transmission of untreatable gonorrhoea globally.